Division of Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Informatics, Decision-Enhancement and Analytic Sciences Center, VA Salt Lake City, Salt Lake City, Utah, USA.
J Neurotrauma. 2021 Dec;38(23):3235-3247. doi: 10.1089/neu.2021.0062. Epub 2021 Aug 17.
Although many patients diagnosed with traumatic brain injury (TBI), particularly mild TBI, recover from their symptoms within a few weeks, a small but meaningful subset experience symptoms that persist for months or years after injury and significantly impact quality of life for the person and their family. Factors associated with an increased likelihood of negative TBI outcomes include not only characteristics of the injury and injury mechanism, but also the person's age, pre-injury status, comorbid conditions, environment, and propensity for resilience. In this article, as part of the Brain Trauma Blueprint: TBI State of the Science framework, we examine the epidemiology of long-term outcomes of TBI, including incidence, prevalence, and risk factors. We identify the need for increased longitudinal, global, standardized, and validated assessments on incidence, recovery, and treatments, as well as standardized assessments of the influence of genetics, race, ethnicity, sex, and environment on TBI outcomes. By identifying how epidemiological factors contribute to TBI outcomes in different groups of persons and potentially impact differential disease progression, we can guide investigators and clinicians toward more-precise patient diagnosis, along with tailored management, and improve clinical trial designs, data evaluation, and patient selection criteria.
尽管许多创伤性脑损伤(TBI)患者,特别是轻度 TBI 患者,在几周内就能从症状中恢复,但仍有一小部分患者在受伤后数月或数年仍持续出现症状,这对患者及其家庭的生活质量产生重大影响。与 TBI 不良结局发生几率增加相关的因素不仅包括损伤和损伤机制的特征,还包括患者的年龄、受伤前的状态、合并症、环境和适应能力。在本文中,作为“颅脑创伤蓝图:TBI 科学现状”框架的一部分,我们检查了 TBI 的长期结局的流行病学,包括发病率、患病率和危险因素。我们发现需要对发病率、恢复和治疗进行更多的纵向、全面、标准化和验证评估,以及对遗传学、种族、民族、性别和环境对 TBI 结局影响的标准化评估。通过确定流行病学因素如何在不同人群的 TBI 结局中发挥作用,并可能影响疾病的不同进展,我们可以为研究人员和临床医生提供更精确的患者诊断以及个性化的管理,并改善临床试验设计、数据评估和患者选择标准。